CRISPR Therapeutics AG (MEX:CRSP) Other Gross PPE : MXN6,535 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CRISPR Therapeutics AG Other Gross PPE?

CRISPR Therapeutics AG's Other Gross PPE for the quarter that ended in Sep. 2024 was MXN6,535 Mil.

CRISPR Therapeutics AG's quarterly Other Gross PPE increased from Mar. 2024 (MXN5,578 Mil) to Jun. 2024 (MXN6,113 Mil) and increased from Jun. 2024 (MXN6,113 Mil) to Sep. 2024 (MXN6,535 Mil).

CRISPR Therapeutics AG's annual Other Gross PPE increased from Dec. 2021 (MXN5,976 Mil) to Dec. 2022 (MXN6,560 Mil) but then declined from Dec. 2022 (MXN6,560 Mil) to Dec. 2023 (MXN5,749 Mil).

CRISPR Therapeutics AG Other Gross PPE Historical Data

The historical data trend for CRISPR Therapeutics AG's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Other Gross PPE Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

1,500.16

2,022.84

5,976.10

6,560.37

5,748.57

CRISPR Therapeutics AG Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Gross PPE	Get a 7-Day Free Trial															5,932.09	5,748.57	5,577.55	6,113.44	6,535.17

CRISPR Therapeutics AG Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

CRISPR Therapeutics AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (MEX:CRSP) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

CRSP:USA 0VRQ:UK

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.